Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

Click for more information

2.19%

93.5¢ mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-254

First 254 Last

Share
Profile

Follow
Phaedrus

1,472 Posts.

3237

13/03/24

06:00

Post #: 72857756
Share

Originally posted by Blackkkkkkk: ↑

Hi All

Thanks for all your replies, and yes, my question was in relation to the approval pathway for gvhd for kids, in a hypothetical scenario where the FDA accepts in the upcoming meeting the additional potency assay that's been provided by MSB as satisfactory response to its complete response letter. Sorry for posting this question in the wrong thread (must have been the reason for the confusion), but I just wanted some clarity on, in this hypothetical scenario:

1. Does MSB have to submit a new BLA including the additional assay and be subjected to the normal review period, or does MSB have the benefit of a rolling review for gvhd for kids as well?
2. In either case, what would be the anticipated review period by the FDA to grant full approval on gvhd for kids?
3. Assuming FDA is not going to approve gvhd for kids "on the spot" (i.e. at the meeting) as it will be subject to a review process, what is the "best" ASX announcement that we can expect to hear from MSB after the meeting?

Expand

I think you'll find answers to many of your questions here: https://www.fda.gov/media/84417/download

Regarding content of any post-meeting announcements, we'll have the real thing in short order, IMO.

GLTAH

MSB Price at posting: 39.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: Local bourse to trade green | Thursday September 12

MAY

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

LU7

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

PIQ

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

There are more pages in this discussion • 296 more messages in this thread...

First 254 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 93.5¢		Change 0.020(2.19%)		Mkt cap ! $1.067B

Open	High	Low	Value	Volume
92.0¢	94.5¢	92.0¢	$1.622M	1.742M

Buyers (Bids)

No.	Vol.	Price($)
4	64563	93.0¢

Sellers (Offers)

Price($)	Vol.	No.
94.0¢	204239	3

View Market Depth

No.	Vol.	Price($)
1	6000	0.990
1	387	0.955
1	150	0.940
1	86	0.935
1	5000	0.930

Price($)	Vol.	No.
0.890	7347	1
0.940	88552	2
0.945	6569	1
0.950	51000	2
0.955	22000	1

Last trade - 16.10pm 11/09/2024 (20 minute delay)

MSB (ASX) Chart